15^th International Conference on Genomics and Molecular Biology March 28-29, 2022 Berlin, Germany

Amal Brahimi, 26 years old women. She is an agronomist engineer since 2016. In addition she is second year PhD student at the Moulay ismail University, Meknes Morocco. She is a member of the 1Laboratory of vegetal Biotechnology and molecular biology. In January 2019, she has done training at the Department of Plants and Crops, Faculty of Bioscience Engineering, Ghent University, for the genetic analysis.

Plant Genomics and Molecular Plant Sciences

Donato Gemmati is professor in Medical Genetics, Section of Medical Biochemistry, Molecular Biology & Genetics, University of Ferrara, Italy and Director of the Interdepartmental Research Center of Haemostasis & Thrombosis, University of Ferrara, Italy. He was born in Rome, Italy (12 Jan 1963), Specialized in Medical Genetics (2006) and PhD in Biomedical Sciences (2009), University of Ferrara, Italy. Board member of the Molecular Medicine PhD Course, University of Ferrara, Italy. Editorial board member: ì. International Journal of Molecular Sciences (Molecular Genetics and Genomics section); ìì. Genes (Human Genomics and Genetic Diseases section).

Molecular Genetics and Genomics section, Genes Human Genomics and Genetic Diseases section

With more than 20 years of experience in the life science industry, Peter is heading market and application development at Samplix. Here efforts are currently focused on the recently launched Xdropâ„¢ technology which introduces an entirely new concept for target enrichment for both short and long read sequencing. Prior to joining Samplix Peter was Global Head of QIAGEN Genomic Services in Germany and the US and before joining QIAGEN, he was heading R&D at Exiqon overseeing life Science Product Development, Diagnostics, and Services.

life Science Product Development, Diagnostics, and Services.

Dimitrios P. Nikolelis received his PhD from University of Athens in 1976 and he is a professor of analytical and environmental chemistry in Department of Chemistry, University of Athens. Prof. Dimitrios Nikolelis has coordinated 3 European Projects on environmental biosensors (CIPA96-0231, IC15-CT96-0804 and QLK3-2000-01311). He also was twice a. NATO Director in the following Advanced Research Workshops: 1. Biosensors for Direct Monitoring of Environmental Pollutants in Field, Smolenice, Slovakia,: May 1996 and 2. Portable biosensors for the Rapid Detection of Biochemical Weapons of Terrorism, July 2012. Prof. Dimitrios Nikolelis has over 200 scientific papers in scientific journals and conferences. He is the Editor of 5 books on Biosensors (1. Biosensors for Direct Monitoring of Environmental Pollutants in Field, Springer, 1996, 2. Portable Chemical Sensors- Weapons against Bioterrorism, Springer, 2012 and 3. Portable Biosensing of Food Toxicants and Environmental Pollutants, CRC, 2013 3. 4. Biosensors for Security and Bioterrorism Applications, Springer, 2014. 5. Nanotechology and biosensors: recent advances, Elsevier, 2017. He is the Editor of many scientific journals. His research is targeted on the fabrication of portable biosensors for in the field uses and he has authored a large number of scientific papers on the detection of environmental pollutants such as hydrazines, dioxins, insecticides, toxins, etc. His current interests also include the construction of novel chemical nanosensors that can be used for the rapid detection of environmental pollutants directly in the gas phase. Prof. D. P. Nikolelis group has recently utilized graphene and ZnO to develop chemical nanosensors based on polymer lipid films for species of clinical or food significance such as urea, uric acid, cholesterol, etc. In progress, there is the evaluation and validation of nanosensors that are based on stabilized polymerized lipid films supported on glass fiber filters using a dry spot test using optical methods of analysis (i.e., fluorescence) to detect environmental pollutants such as insecticides, plant hormones, toxins, hydrazines, etc.

Biosensors, Blood serum, Nano sensors, Chemistry

Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993). He is now retired and living in the Adirondacks in New York, USA.

Molecular Biophysics, Physical-chemistry, Genomics

Chair, Department for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Professor, Dept for Immunology, A.I.Evdokimov Moscow State University of Medicine & Dentistry, Moscow, Russia

Medicine

Patrizia Zavattari, received the M.Sc. degree in Biological Sciences at Pisa University (Italy) and the PhD at Cagliari University (Italy). She is Associate Professor of Experimental Biology and Genetics at Cagliari University, teaching in the Faculties of Biology, Pharmacy and Medicine. She is the Head of a Molecular Biology, Genomics and Epigenomics Laboratory.

Her research interests are mainly focused on molecular oncology and complex traits. She worked both abroad (Paris, Oxford, Cambridge, Philadelphia) and in Italy (Milan, Novara). She is co-author of about forty publications. Since 2011 she is Review Editor of Frontiers and she reviews for various scientific journals.

Jane Xiao has obtained her PhD in Analytical Chemistry at University of Wales Swansea, UK. She is a Co-Founder and Senior Director in Biologics Characterization at Axcel BioPartners. Prior to that, she served as Director at Oncobiologics, Head of a proteomics lab at Johnson & Johnson and Senior Scientist at Merck.

For the last 15 years she has worked for the pharmaceutical industry leading analytical method development for protein characterization, biomarker development in early phase clinical trials, biosimilar development for similarity assessment and comparability assessment.

Dr. Nickerson obtained a Ph.D. in Molecular Medicine from the George Washington University. He has made significant contributions to disease gene identification using positional cloning, including an altered Birt-Hogg-Dubé gene in chromophobe RCC, fumarate hydratase in papillary RCC, the dead-end gene in testicular cancer, and the UBIAD1 gene in Schnyder Corneal Dystrophy. More recently, he has sequenced urologic tumor genomes and identified alterations in TET2 in prostate cancer and the BRCA pathway in bladder and kidney cancer, which have been translated to a clinical trial starting in 2016. He is an active participant in Precision Medicine, ClinVar and the TCGA project.

Urologic Cancer Genetics, Genetics of Bladder Cancer, Genetics of Prostate Cancer, Genetics of Kidney Cancer.

Dr. Lamba, Ph.D., is an Associate Professor of the Department of Pharmacotherapy and Translational Research. Dr. Lamba did Ph.D in the field of Pharmacogenomics from Postgraduate Institute of Medical Education and Research in Chandigarh, India and did post-doctoral training at St. Jude Children’s Research Hospital, Memphis; TN.Dr. Lamba’s research has been funded from NIH/NCI since 2008 and focuses on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients specifically Acute Myeloid Leukemia. Her research spans from preclinical basic research comprising the discovery phase to translational/clinical phase in patient populations from multi-institute clinical trials.

Dr. Lamba has around 20 years of expertise, training and knowledge skills in the field of pharmacogenomics. Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients with special focus on Acute Myeloid leukemia. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials.